Private Capital Advisors Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 12,457 shares of the biopharmaceutical company’s stock after purchasing an additional 4,250 shares during the quarter. Private Capital Advisors Inc.’s holdings in Gilead Sciences were worth $1,009,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of GILD. Bank of New York Mellon Corp lifted its position in Gilead Sciences by 11.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after buying an additional 3,221,439 shares in the last quarter. Northern Trust Corp lifted its position in Gilead Sciences by 2.0% during the 2nd quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock worth $1,191,754,000 after buying an additional 325,246 shares in the last quarter. Sanders Capital LLC lifted its position in Gilead Sciences by 7.0% during the 2nd quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after buying an additional 696,200 shares in the last quarter. Boston Partners lifted its position in Gilead Sciences by 3.1% during the 2nd quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock worth $587,300,000 after buying an additional 245,805 shares in the last quarter. Finally, OppenheimerFunds Inc. lifted its position in Gilead Sciences by 0.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock worth $498,599,000 after buying an additional 22,916 shares in the last quarter. 77.99% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts recently issued reports on GILD shares. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. BidaskClub upgraded shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 26th. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Wells Fargo & Co upped their price target on shares of Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Monday, October 1st. They set an “overweight” rating and a $87.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $88.24.
Gilead Sciences stock opened at $73.59 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54. The stock has a market cap of $100.09 billion, a price-to-earnings ratio of 8.60, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The company had revenue of $5.65 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the prior year, the company posted $2.56 EPS. The company’s revenue was down 20.9% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 27th. Shareholders of record on Friday, September 14th were given a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.10%. Gilead Sciences’s payout ratio is presently 26.64%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $239,408,146.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 150,000 shares of company stock worth $11,502,500. Corporate insiders own 1.16% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Understanding Relative Strength Index
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.